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groups, costs were analyzed using a propensity score
model. Conﬁdence intervals were estimated using boot-
strap methods. RESULTS: Population in the two groups
was balanced for age, gender, weight and body mass
index. The groups differed signiﬁcantly in terms of
housing status (p < 0.05) and nutritional status (p <
0.001). Adjusted costs per patient of hospital care 
(-€551), nursing care (-€145) and other medical care
were signiﬁcantly reduced in the FNS group as compared
to the LNS group, with cost savings of -€723 (90% CI:
-€1.444 to -€43). Including oral supplementation costs,
the total cost savings per patient attributable to nutrition
support were -€195 (90% CI: -€929 to +€478). CON-
CLUSION: Appropriate nutrition diagnosis and support
may contribute to reduce the costs of health care. Propen-
sity score models are a valuable framework for the analy-
sis of cost data, when it is not possible to conduct
randomized studies.
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OBJECTIVE: To compare the efﬁciency of leﬂunomide-
methotrexate or inﬂiximab-methotrexate in patients 
with rheumatoid arthritis resistant to methotrexate.
METHODS: Cost-minimization pharmacoeconomic
model that compared treatments administered at the 
recommended doses and regimens during a 12-month
period. Use of resources and unit costs were estimated
from Spanish sources. Simple univariate sensitivity analy-
sis was made of the base case. RESULTS: In two 
randomized, placebo-controlled clinical trials available,
the ACR20 and ACR50 responses rates at 6 months 
were 46.2% and 25.4%, respectively, with leﬂunomide-
methotrexate and 50.0% and 27.0%, respectively, with
inﬂiximab-methotrexate (2P = 0.57 and 2P = 0.82). The
estimated cost per patient of annual treatment with
leﬂunomide-methotrexate or inﬂiximab-methotrexate is
€2,823 versus €11,489, respectively (incremental cost of
€8,666). Sensitivity analysis conﬁrmed the robustness 
of the base case, with incremental costs of inﬂiximab-
methotrexate ranging from €7,500 to €9,500. In order to
equalize the costs per patient of these alternatives, the cost
of acquisition of a package of Inﬂiximab would have to
decrease from the present €637.59 to a hypothetical 
cost of €33.10. CONCLUSIONS: The cost per patient 
of twelve months of treatment with the combination of
inﬂiximab-methotrexate is greater than that of leﬂuno-
mide-methotrexate, due mainly to the higher acquisition
cost of Inﬂiximab.
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OBJECTIVES: To examine the sick rate of rheumatoid
arthritis in Ukraine in 1996 to 2001. Celecoxib is a new
COX-2-inhibitor drug. Randomized controlled clinical
trials—RCCTs showed, that celecoxib is safer than 
non-steroidal anti-ﬂammatory drugs (NSAIDs). To
analyse direct medical costs for treatment celecoxib vs
NSAIDs with gastroprotective agents in patients with
rheumatoid arthritis from the perspective of public health
care in Ukraine. METHODS: A decision tree model in
Ukraine based on the use of clinical data from literature.
Eight RCCTs showed a signifﬁcantly higher incidence of
ulcer—the 6-month rates of ulcer were 5,89% for
NSAIDs vs 1,64% for celecoxib, and for NSAID plus
proton-pump ingibitor (PPI)—1,94%. Only direct costs
associated with three alternatives: celecoxib; NSAID 
only; NSAID plus PPI (six months) were analysed. All
prices are expressed in Ukranian hryvnas (UAH). The
incremental cost-effectiveness ratio was determined.
RESULTS: The sick rate of rheumatoid arthritis from
1996 to 2001 was increased 8,6% per year in Ukraine.
The direct costs of celebrex and NSAID only were com-
parable 905,4 UAH vs 897,5 (1USD = 5,2 UAH), but the
NSAID plus PPI was signiﬁcantly more costly 1216,1
UAH per one patient. The incremental cost-effectiveness
ratio for celecoxib was 1,86 UAH; NSAID plus PPI—80,6
UAH per 1% of ulcer reduction. The total cost of 100
patients treated with celecoxib was 90540 UAH than
NSAIDs plus PPI was 95822 UAH. The threshold analy-
sis suggests that celecoxib would be the dominant therapy
if its cost was to decrease by 58%. CONCLUSIONS: The
treatment with Celecoxib is more effective and safe than
NSAID only, and to be cost-effective than NSAID plus
PPI in Ukraine.
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OBJECTIVES: To investigate the variation in resource
utilization and treatment costs for moderate to severe RA
patients in ﬁve countries (Australia, Canada, France,
Germany, UK). METHODS: Resource utilization was
collected alongside a 6-month multinational phase-III
clinical trial assessing the safety and efﬁcacy of Adali-
mumab (D2E7), a fully human anti-TNF antibody,
among 325 established RA patients who failed previously
3.7 DMARDs and had a 11-year mean disease duration
(DE011/DE026). Data on 54 resource utilization items
were collected including direct costs (e.g. hospitalizations,
procedures, medications); direct non-medical costs (e.g.
transportation, devices), and indirect costs (e.g. produc-
tivity loss, family support) during 12 months of living
with RA. Resources were valuated using country-speciﬁc
prices and standardized to 2001US$. A human-capital
approach was employed to estimate productivity losses.
RESULTS: Mean societal total cost was US$7174
(SEM471) per patient across all countries. However sig-
niﬁcant variation existed at the country-level. The UK 
had the highest societal total cost: US$9277 (SEM1876)
followed by France US$9275 (SEM1155), Germany
US$7448 (SEM951), Canada US$6347 (SEM855) and
Australia US$5174 (SEM711). 95% of total costs were
explained by direct costs in the UK compared to 70% in
Germany, where lost productivity was a larger factor. Of
direct costs, hospital inpatient costs contributed almost
44.5% (Germany), 40.3% (UK), 36.9% (Australia),
33.5% (France) and 13.1% (Canada). Medical to non-
medical direct cost ratios varied from 1 :1 in Australia to
almost 1 :2 in the UK. CONCLUSIONS: These results are
consistent with the mean cost of US$6270 estimated from
a systematic review of 11 US and 4 European studies
(Cooper, Rheumatology 2000). Treatment costs are 2.5
times greater in this study of longstanding severe RA
patients than in published studies of early RA patients.
This study provides a comprehensive picture of health-
care services used for the treatment of RA patients and
indicates that pronounced country differences exist.
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OBJECTIVES: COX-2 inhibitors (COXIBs) have been
introduced in Italy in September 2000. We investigated
and identiﬁed differences in history of claims for 
gastrointestinal disorders (GIDs) between COXIBs vs
NSAIDs patients. METHODS: Prescriptions of antin-
ﬂammatories made by 200GPs to a population of 24,428
arthritis patients in a Northern Italian area were retro-
spectively investigated, focused on the ﬁrst six months 
of COXIBs availability (1st October 2000–31st March
2001). COXIBs were prescribed to 6,204 patients and
NSAIDs to 18,224 patients. We extracted the data of 
all 442 COXIB patients who received a co-prescription
(i.e.simultaneously prescribed at least once in the obser-
vation period) of a gastroprotective agent (GPA). COXIB
+ GPAs patients were compared to a sample of 442
NSAIDs + GPAs patients, matched for age and gender.
The two groups were compared in terms of history of
claims for GIDs, including GPA prescription, diagnostic
procedures, and hospitalizations, occurred in the course
of the previous 2 years (1st October 1998–30th Septem-
ber 2000). Reimbursed prices, for drugs, and tariffs paid
by NHS, for procedures and hospitalizations, were used
to calculate costs. RESULTS: Prior to starting their COX-
2 treatment, 84% of COXIB + GPAs patients vs 79% of
NSAIDs + GPAs patients had a history of GID with sig-
niﬁcantly higher (p = .0026, U test) mean costs (€554.9
vs €362.6). All cost items were higher in the former
group: hospitalizations (€185.8 vs 76.8), procedures
(€52.5 vs 43.2), GPAs (€316.6 vs 242.6). CONCLU-
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